OptimizeRx Corporation
OPRX
$9.20
-$0.79-7.91%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 92.13M | 88.18M | 83.20M | 78.21M | 71.52M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 92.13M | 88.18M | 83.20M | 78.21M | 71.52M |
| Cost of Revenue | 32.75M | 32.98M | 31.65M | 30.54M | 28.62M |
| Gross Profit | 59.38M | 55.20M | 51.55M | 47.67M | 42.90M |
| SG&A Expenses | 61.27M | 58.56M | 58.02M | 55.85M | 53.71M |
| Depreciation & Amortization | 4.33M | 4.24M | 3.61M | 3.01M | 2.40M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 98.34M | 95.78M | 93.29M | 89.39M | 84.74M |
| Operating Income | -6.22M | -7.60M | -10.08M | -11.18M | -13.22M |
| Income Before Tax | -19.38M | -33.33M | -26.26M | -25.29M | -25.13M |
| Income Tax Expenses | 725.00K | -9.16M | -8.34M | -7.22M | -7.57M |
| Earnings from Continuing Operations | -20.11 | -24.17 | -17.91 | -18.07 | -17.57 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.11M | -24.17M | -17.91M | -18.07M | -17.57M |
| EBIT | -6.22M | -7.60M | -10.08M | -11.18M | -13.22M |
| EBITDA | -1.89M | -3.57M | -6.58M | -8.23M | -10.82M |
| EPS Basic | -1.10 | -1.33 | -1.00 | -1.03 | -1.02 |
| Normalized Basic EPS | -0.41 | -0.43 | -0.46 | -0.44 | -0.44 |
| EPS Diluted | -1.10 | -1.34 | -1.01 | -1.04 | -1.03 |
| Normalized Diluted EPS | -0.41 | -0.43 | -0.46 | -0.44 | -0.44 |
| Average Basic Shares Outstanding | 73.17M | 72.53M | 70.84M | 69.58M | 68.50M |
| Average Diluted Shares Outstanding | 73.17M | 72.53M | 70.84M | 69.58M | 68.50M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |